Supriya Lifescience Ltd (SLL), a leading pharmaceutical company, inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at its Lote Parshuram site in Maharashtra on December 17, 2024. The new facility, developed with an investment of ₹125 crore, adds a 335-kiloliter capacity, increasing the site’s total production from 597 KLPD to 932 KLPD – a growth of over 55%.
Strategic Focus on Innovation and Efficiency
The new Module E block aligns with SLL’s strategic focus on expanding R&D capabilities and scaling up its innovative product pipeline. The facility will play a pivotal role in the commercialization of niche therapeutic products, reinforcing SLL’s commitment to backward integration and global leadership in the pharmaceutical sector.
Key Features of the Facility:
- Backward Integration Model: Ensures economies of scale and a competitive edge.
- Infrastructure: Spanning 5,000 sq. meters over four levels, enabling efficient operations and safe workflows.
- Advanced Equipment: Includes 33 reactors made of stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL.
- Optimized Process Design: Gravity-based flows enhance safety, efficiency, and product integrity.
- Automation: Incorporates closed-system handling, process control, and material handling systems to meet the latest quality standards.
- Adaptable Operations: Equipped for diverse unit processes to ensure scalability for future needs.
Leadership Perspective
Dr. Satish Wagh, Executive Chairman & WTD of Supriya Lifescience Ltd, highlighted:
“Module E is a testament to our strategic focus on innovation and sustainability, serving as a key driver of growth while reducing dependence on imports. With the latest technologies, we are poised to elevate product quality, ensure efficiency, and meet growing global demand.”
About Supriya Lifescience Ltd
Founded in 1987, Supriya Lifescience is a globally renowned producer of APIs and intermediates, serving innovators and generic firms worldwide. Headquartered in Mumbai, the company holds certifications from Health Canada, USFDA, WHO, and other global regulatory bodies, with a robust R&D foundation supporting over 14 active USDMFs and 8 CEPs.
With the launch of Module E, SLL further solidifies its position as a key player in the pharmaceutical industry, setting new benchmarks in manufacturing excellence and global competitiveness.
